Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed)
Notice Number:

Key Dates

Release Date:
April 11, 2022
Estimated Publication Date of Funding Opportunity Announcement:
July 29, 2022
First Estimated Application Due Date:
September 30, 2022
Earliest Estimated Award Date:
July 03, 2023
Earliest Estimated Start Date:
July 03, 2023
Related Announcements

NOT-CA-22-074 - Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)

NOT-CA-22-075 - Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Issued by

National Cancer Institute (NCI)


The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT network, facilitate data sharing and collaboration, and coordinate clinical trial activities between research sites and the NCI.

This notice is being provided to allow potential applicants sufficient time to develop a responsive grant application. The FOA is expected to be published in July 2022 with an expected application due date in September 2022. Details of a planned pre-application webinar will be announced in the Guide after publication of the FOA. This FOA will utilize the U24 activity code.

Research Initiative Details

This Notice encourages investigators with expertise and insights into the area of adoptive cell therapy clinical trials for the treatment of cancer to begin to consider applying for this new FOA.

Clinical trials conducted through Can-ACT will be supported by the Immune Cell Network Core Facility (ICN Core) at the Frederick National Laboratory for Cancer Research (FNLCR). The ICN Core will provide GMP capabilities for molecularly modifying immune cells, producing vectors, and standardizing cell characterization assays for clinical testing, as well as supporting the collection and harmonization of multi-site clinical trial data. The Coordinating Center for Can-ACT will primarily be responsible for organizing efforts between clinical trial sites and the ICN Core.

The Coordinating Center will also provide leadership to the Can-ACT network by:

  • Organizing meetings for the research sites;
  • Forming a Steering Committee for the Can-ACT network;
  • Establishing an External Advisory Committee; and
  • Providing overall guidance for the further development of the ICN Core and Can-ACT Network.
Funding Information


Estimated Total Funding

$500,000 in total costs

Expected Number of Awards


Estimated Award Ceiling

$225,000 direct costs per year

Primary Assistance Listing Number(s)


Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 


Please direct all inquiries to:

Kasia Bourcier, Ph.D.

National Cancer Institute (NCI)


Laura Hunter, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5344